**1. Introduction**

The worldwide increase in obesity at paediatric ages has been accompanied by the appearance of diseases that were considered exclusive of adults, namely type 2 diabetes (T2D), dyslipidaemia and hypertension. These pathologies are commonly associated with central obesity, and this association is related with increased cardiometabolic risk [1, 2].

Obesity is closely associated with hypoadiponectinaemia, and low levels of circulating adiponectin are a potential predictor of some obesity‐related co‐morbidities. Therefore, adiponectin has been studied as a possible link between these conditions. Furthermore, growing evidence supports a relationship between obesity in childhood and low levels of adiponectin, and increased cardiometabolic risk factors in adulthood [3, 4].
